{'fraction_non_alphanumeric': 0.02936630602782071, 'fraction_numerical': 0.02009273570324575, 'mean_word_length': 5.230769230769231, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Physostigmine in familial ataxias

Article abstract Physostigmine was given to 12 patients with various spinocerebellar degenerations, and neurologic examinations were recorded on video tapes and assessed on a semiquantitative scale. Forty minutes after a single dose, the scores improved by 35.7 ± 4.7 percent (means ± SEM). Eight patients were then studied over sequential 3-month periods by a randomized double-blind trial of physostigmine versus placebo. With physostigmine, scores were 33.9 ± 8.3 percent better than before treatment or with placebo. Further investigations of cholinergic drugs seem warranted in patients with these diseases.